Last reviewed · How we verify
Standard Maintenance
Standard Maintenance refers to a continuation therapy regimen rather than a specific drug with a defined molecular mechanism.
Standard Maintenance refers to a continuation therapy regimen rather than a specific drug with a defined molecular mechanism. Used for Lymphoma (maintenance phase, specific subtype not specified).
At a glance
| Generic name | Standard Maintenance |
|---|---|
| Also known as | Rituximab |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This appears to be a protocol designation from Fondazione Italiana Linfomi (Italian Lymphoma Foundation) for a Phase 3 trial, likely describing a maintenance treatment phase following induction therapy in lymphoma. Without specification of the active agent(s), the mechanism cannot be precisely defined, but maintenance therapy in lymphoma typically aims to sustain remission and delay relapse.
Approved indications
- Lymphoma (maintenance phase, specific subtype not specified)
Common side effects
Key clinical trials
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Running Environments on Physiological Responses, Emotion, Motivation, and Attention (NA)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- IASTM and Vibration Effects on Pain, Functionality, and Kinesiophobia in Lumbar Disc Herniation (NA)
- Exercise for the Treatment of Cancer-Related Sarcopenia (NA)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Maintenance CI brief — competitive landscape report
- Standard Maintenance updates RSS · CI watch RSS
- Fondazione Italiana Linfomi - ETS portfolio CI